|
About MaxThera
MaxThera, Inc. is a biopharmaceutical company focused on developing new drugs to treat bacterial infections, especially those resistant to existing antibiotics. Antibiotics kill bacteria by disrupting vulnerable sites (targets) within biological pathways essential for bacterial survival. Most antibacterial drugs function by acting against one of only a handful of targets. Similarities in chemical composition (structure) for generations of drugs, and a limited number of targets, have been key drivers in building resistance.
MaxThera is different: The Company has a portfolio of potential products — proprietary drug candidate structures that inhibit unique targets. MaxThera’s strategy to limit resistance emergence is to combine these new targets in new pathways — essential for bacterial survival — with new drug structures. With these dramatically different drugs, rapid resistance development, as has been common with current drugs, will be unlikely.
MaxThera’s portfolio of new targets and new inhibitor structures represent an opportunity for a true breakthrough in antibacterial drug discovery.
|
